DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
EAGAN, Minn., Sept. 28, 2017 -- Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera’s novel phase 2 cancer immunotherapy. These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI-EORTC will feature initial translational research from Biothera’s ongoing phase 2 clinical study combining Imprime PGG and Merck’s anti-PD-1 antibody, Keytruda®, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.
American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, Boston, MA, October 1-4, 2017
| Session Date & Time | Monday, October 2, 2017, 5:30pm to 7:30pm ET |
| Session | Poster Session A |
| Presentation Title | Imprime PGG, a soluble yeast β-glucan PAMP, synergizes with anti-PD-1 antibody to enhance CD8 T cell anti-tumor immunity |
| Session Location | Boston Marriott Copley Place, Back Bay |
| Abstract Number | A18 |
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, October 26-30, 2017
| Session Date & Time | Saturday, October 28, 2017, 12:30pm-4:00pm, ET |
| Session | Immune Modulators, Late-Breaking Poster Session A |
| Presentation Title | Imprime PGG (Imprime) plus pembrolizumab (PEM): a phase 2 immunotherapeutic combination in patients selected for an Imprime-specific biomarker |
| Session Location | Hall E, Pennsylvania Convention Center |
| Abstract Number | LB-A31 |
| Session Date & Time | Sunday, October 29, 2017, 12:30pm to 4:00pm ET |
| Session Category | Immune Modulators |
| Session Title | Poster Session B |
| Presentation Title | Imprime PGG, a soluble yeast β-glucan PAMP, activates both innate and adaptive immune effector cells, resulting in enhanced antitumor responses that synergize with anti-PD-1 antibody therapy |
| Session Location | Hall E, Pennsylvania Convention Center |
| Poster Board Number | 9 |
| Abstract Number | B009 |
Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting, National Harbor, MD, November 8-12, 2017
| Session Date & Time | Saturday, November 11, 2017, 12:30 – 2pm and 6:30 – 8pm ET |
| Presentation Titles: | Increasing the levels of anti-beta glucan antibodies by administration of intravenous immunoglobulin (IVIG) induces immunopharmacodynamic (IPD) responses of a novel immunotherapeutic Imprime PGG |
| Session Location: | Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall DE |
| Abstract Number: | P74 |
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact:
David Walsh
Biothera Pharmaceuticals, Inc.
651-256-4606
[email protected]
